SRAX.OTC.PinkSrax, INC

8-K: SRAX to Merge with Web3 Investment Firm DNA Holdings, Creating New Publicly Traded Entity

Sentiment:

Merger Announcement


SRAX Inc. has entered into a definitive merger agreement with DNA Holdings Venture Inc., which will result in DNA's shareholders becoming the majority owners of SRAX's outstanding common stock.

Capital raiseDNA will advance SRAX at least $500,000 on or prior to the closing of the Merger.Merger Partner shall have the absolute and unconditional right to engage in Pre-Closing Private Placement Transactions involving the raising of funds, issuance of equity securities or other rights of Merger Partner.
Worse than expectedThe merger will result in significant dilution for existing SRAX shareholders, as DNA's shareholders will own approximately 75.5% of the outstanding shares.

Summary

  • SRAX, a financial technology company, has agreed to merge with DNA Holdings Venture Inc., a Web3 investment company.
  • Upon completion of the merger, DNA's shareholders will own approximately 75.5% of the outstanding shares of the combined company, including the 35% of SRAX that DNA already owned.
  • SRAX will issue 1,000 shares of a newly created Series C Convertible Preferred Stock to DNA's shareholders as consideration for the merger.
  • The combined company will change its name to DNA Holdings Venture Inc. and will seek a new ticker symbol.
  • DNA Holdings focuses on Web3 investments, advisory services, and community events, with a portfolio including projects like Tether, Blockchain Capital, and Hedera Hashgraph.
  • The merger is subject to customary closing conditions, including approval by DNA's shareholders and SRAX becoming current in its SEC reporting obligations.
  • DNA will advance SRAX at least $500,000 prior to the closing of the merger.

Sentiment

Score: 6

Explanation: The document presents a significant strategic shift for SRAX, with a focus on the high-growth Web3 sector. While the merger brings potential benefits, the dilution for existing shareholders and the risks associated with the transaction temper the overall positive sentiment.

Positives

  • The merger provides SRAX with access to DNA's expertise in the rapidly growing Web3 market.
  • SRAX's investor platform, Sequire, is expected to benefit from DNA's insights and connections.
  • The combined entity will be positioned to capitalize on the opportunities in decentralized finance and tokenization.
  • DNA's co-founders have a strong track record in Web3 investments.
  • The merger will create a publicly traded company focused on Web3 technology projects.

Negatives

  • The merger will result in significant dilution for existing SRAX shareholders.
  • The transaction is subject to several closing conditions, including shareholder approvals and SRAX becoming current with its SEC filings, which could delay or prevent the merger.
  • SRAX is required to obtain consents from its senior secured creditors and warrantholders.
  • The merger agreement contains termination rights for both SRAX and DNA.

Risks

  • The merger may not be completed if the closing conditions are not met.
  • Legal proceedings related to the merger could delay or prevent its completion.
  • Unanticipated difficulties or expenditures related to the merger could arise.
  • The response of business partners and competitors to the merger announcement could negatively impact the companies.
  • Employee retention could be a challenge during the merger process.
  • SRAX needs to become current in its reporting obligations with the SEC, which could be a risk.

Future Outlook

The combined company plans to change its name to DNA Holdings Venture Inc. and to request a new ticker symbol, creating a public company focused on Web3 technology projects. The parties believe that SRAX's ability to reach a database of millions of investors is uniquely positioned to educate and inform on the benefits of investing in the decentralized ecosystem. SEQUIRE intends to work with their clients to help them explore methods by which they can capitalize from decentralized finance and the tokenization opportunities.

Management Comments

  • Brock Pierce, Co-Founder of DNA, stated that they believe SRAX provides the perfect vehicle for DNA to begin its journey as a public company.
  • Scott Walker, Co-Founder of DNA, added that DNA allows new investors to gain exposure to the fast-growing other 50% of the $2T+ Web3 market.
  • Christopher Miglino, Founder and CEO of SRAX, said that merging with DNA will provide SRAX with the expertise to become a leader in the space.

Industry Context

This merger reflects the growing interest and investment in the Web3 space. The combination of a financial technology company with a Web3 investment firm suggests a strategic move to capitalize on the convergence of traditional finance and decentralized technologies. The involvement of prominent figures in the Web3 space, such as Brock Pierce, further highlights the significance of this transaction within the industry.

Comparison to Industry Standards

  • The merger of SRAX and DNA is similar to other recent moves by traditional companies to gain exposure to the Web3 market.
  • The valuation of the combined entity will be determined by the market's perception of the Web3 sector and the potential of DNA's investment portfolio.
  • The success of the merger will depend on the combined company's ability to integrate SRAX's investor platform with DNA's Web3 expertise.
  • The 75.5% ownership stake for DNA's shareholders is a significant majority, indicating a strong strategic shift for SRAX.
  • The involvement of Brock Pierce and Scott Walker, known figures in the Web3 space, adds credibility and potential for growth.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
CEO of the combined entityChristopher Miglino (SRAX)Christopher MiglinoUpon completion of the mergerMerger of the two companies
Chairman of the BoardUnknownChristopher MiglinoUpon completion of the mergerMerger of the two companies
Board of DirectorsUnknownPersons identified on Section 6.10 of the Public Company Disclosure ScheduleUpon completion of the mergerMerger of the two companies
Executive OfficersUnknownPersons identified on Schedule 6.9 of the Public Company Disclosure ScheduleUpon completion of the mergerMerger of the two companies

Stakeholder Impact

  • Existing SRAX shareholders will experience significant dilution due to the issuance of new shares to DNA's shareholders.
  • SRAX employees may experience changes in their roles and responsibilities as a result of the merger.
  • Customers of SRAX may see new product offerings and services related to Web3.
  • DNA's stakeholders will gain access to the public markets through the merger.
  • The merger may create new opportunities for investors interested in the Web3 space.

Next Steps

  • SRAX and DNA will seek approval from their respective shareholders.
  • SRAX will need to become current in its reporting obligations with the SEC.
  • The combined company will change its name and ticker symbol.
  • The companies will work to integrate their operations and platforms.
  • The combined company will explore opportunities in decentralized finance and tokenization.

Key Dates

DateDescription
May 6, 2024Date of the Agreement and Plan of Merger.
May 7, 2024SRAX entered into the definitive Merger Agreement with DNA Holdings Venture, Inc.
May 8, 2024SRAX and DNA issued a joint press release announcing the execution of the Merger Agreement.
May 12, 2024Date of the 8-K report.
December 31, 2024Outside Date for the merger to be completed.

Keywords

merger, Web3, DNA Holdings, SRAX, cryptocurrency, blockchain, investment, decentralized finance, tokenization, Sequire

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.